A First-in-Human Study Evaluating AGA2118 in Postmenopausal Women
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to assess the safety and tolerability of AGA2118
after single subcutaneous or intravenous administration in healthy postmenopausal women and
to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations
in postmenopausal women with low bone mass.